Israel Englander Ayala Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.97 $12,838 - $30,844	-15,657 Reduced 51.22%	14,913 $15,000
Q2 2022 Aug 15, 2022	SELL	$0.99 - $4.15 $41,527 - $174,080	-41,947 Reduced 57.84%	30,570 $33,000
Q1 2022 May 16, 2022	BUY	$3.5 - $9.11 $253,809 - $660,629	72,517 New	72,517 $289,000
Q2 2021 Aug 16, 2021	SELL	$9.2 - $11.3 $114,144 - $140,199	-12,407 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$10.72 - $22.0 $93,210 - $191,290	-8,695 Reduced 41.2%	12,407 $135,000
Q4 2020 Feb 16, 2021	SELL	$9.67 - $13.5 $148,192 - $206,887	-15,325 Reduced 42.07%	21,102 $240,000
Q3 2020 Nov 16, 2020	SELL	$8.8 - $14.55 $223,159 - $368,973	-25,359 Reduced 41.04%	36,427 $429,000
Q2 2020 Aug 14, 2020	BUY	$10.0 - $15.92 $617,860 - $983,633	61,786 New	61,786 $620,000

Ticker AYLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,833,300
Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinic...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.